Compare IDEXX Laboratories, Inc. (IDXX) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Logitech International SA — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Logitech International SA trades at $103.79 (market cap $14.96B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.1× Logitech International SA's market cap, and Logitech International SA pays a 1.64% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | LOGI | |
|---|---|---|
Market Cap | $46.22B | $14.96B |
Sector | Health | Technology |
52-Week High | $766.68 | $126.69 |
52-Week Low | $526.44 | $85.84 |
Enterprise Value | $47.12B | $13.30B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Logitech (LOGI) trades at $101.92, down 2.81% amid technical bearish signals and supply chain concerns. The stock shows strong fundamentals with three consecutive quarterly earnings beats, robust 35.29% ROE, and 16.28% net margins. Recent Q1 2027 results exceeded expectations with $1.85 EPS versus $1.26 expected, though a semiconductor supplier shutdown creates near-term uncertainty.
Outlook remains mixed with 26% upside to consensus $109.75 target but tempered by supply risks. Investment case hinges on Logitech's premium product demand and margin expansion potential, balanced against Q3 2027 supply constraints and divided analyst sentiment (26% Buy, 47% Hold, 26% Sell).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
